VYVGART Hytrulo

NDC 73475-3102 · argenx US

Generic nameefgartigimod alfa and hyaluronidase (human recombinant)

Dosage formINJECTION, SOLUTION

RouteSUBCUTANEOUS

Active ingredient(s)EFGARTIGIMOD ALFA, HYALURONIDASE (HUMAN RECOMBINANT)

Strength180; 2000 mg/mL; U/mL

Pharmacologic classEndoglycosidase [EPC], Glycoside Hydrolases [CS], Neonatal Fc Receptor Blocker [EPC], Neonatal Fc Receptor Blockers [MoA]

Marketing categoryBLA

Packages

73475-3102-3 — 1 VIAL, SINGLE-DOSE in 1 CARTON (73475-3102-3) / 5.6 mL in 1 VIAL, SINGLE-DOSE

Billed under HCPCS

J9334 — Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc Medicare Part B payment limit (ASP + 6%): $34.26

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

0003-3120 — nivolumab and hyaluronidase-nvhy, 0003-6120 — nivolumab and hyaluronidase-nvhy, 18657-117 — Hyaluronidase, 50242-077 — Trastuzumab and hyaluronidase-oysk, 50242-108 — rituximab and hyaluronidase, 50242-109 — rituximab and hyaluronidase, 50242-245 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-260 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-554 — ocrelizumab and hyaluronidase, 50242-933 — atezolizumab and hyaluronidase-tqjs, 51662-1555 — HYALURONIDASE, 57894-503 — daratumumab and hyaluronidase-fihj (human recombinant), 57894-510 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-514 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-515 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-522 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 73475-1221 — efgartigimod alfa and hyaluronidase (human recombinant), 73475-3041 — EFGARTIGIMOD ALFA

From the FDA National Drug Code Directory, retrieved 2026-08-24. Product listings are submitted by labelers; FDA does not verify them.